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Osteoclasts dissolve mineralized bone matrix at bone resorption sites and release large amounts of calcium (Ca2 +) and phosphate (PO4
3)
ions into the extracellular fluid. However, the exact nature of Ca2 + and PO4
3  on osteoblasts remains unclear. We proposed that Ca2 + and
PO4
3 ions are required for the expression of sodium-dependent vitamin C transporter (SVCT) 2 and a differentiation marker, osteopontin
(OPN), in osteoblasts as a response to the osteoclastic degradation. Results from Northern blotting indicated that a deficiency of Ca2 + or PO4
3
inhibited both SVCT2 and OPN expression in a time-dependent manner, whereas elevated Ca2 + (1 to 4 mM) or PO4
3 (1 to 4 mM) dose-
dependently induced SVCT2, OPN expression and OPN promoter activity. In addition, the L-type calcium channel blocker, nifedipine (5 to 20
AM) and the phosphate transporter inhibitor, foscarnet (0.15 to 0.6 mM), dose-dependently abolished Ca2 +- and PO43-induced SVCT2, OPN
expression and OPN promoter activity. Furthermore, the results from L-ascorbic acid uptake assay and Western blotting indicated that the
stimulatory effect of Ca2 + and PO4
3 on functional SVCT2 protein expression. These findings suggested that Ca2 + and PO4
3 regulate
osteoblastic phenotype by entering into cells to stimulate SVCT2 and OPN expression.D 2003 Elsevier Science B.V. All rights reserved.Keywords: Calcium; Phosphate; Sodium-dependent vitamin C transporter; Osteopontin; Ascorbic acid; MC3T3-E1 cells1. Introduction
The process of bone remodeling consists of osteoclastic
bone resorption followed by a period of bone formation,
between which, a dynamic balance maintains skeletal
homeostasis. Many factors such as ions, hormones, growth
factors and cytokines regulate osteoblastic and osteoclastic
functions in the bone microenvironment [1]. At resorption
sites, osteoclasts consume large amounts of energy to drive
hydrochloric acid secretion, which produces calcium (Ca2 +),
phosphate ions (PO4
3) and water from hydroxyapatite that
comprises bone mineral. Concentrations of Ca2 + fluctuate
dramatically, reaching as high as 40 mM in the local micro-
environment [2]. Much evidence suggests that high concen-
trations of Ca2 + stimulate osteoblast proliferation and inhibit
osteoclastic resorption [3–6]. Alternatively, PO4
3 induces0167-4889/03/$ - see front matter D 2003 Elsevier Science B.V. All rights reserv
doi:10.1016/S0167-4889(03)00065-X
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and Ca2 + can accentuate the apoptogenic effect of PO4
3
[7,8]. A recent study has also indicated that as osteoblasts
mature, osteoclast formation decreases, whereas alkaline
phosphatase (ALP) activity and inorganic phosphate in the
extracellular matrix increase. Since extracellular PO4
3 sup-
presses osteoclast formation, phosphate released by ALP
may be related not only to mineralization but also to the
suppression of osteoclastogenesis [9]. Therefore, except for
the bone components, Ca2 + and PO4
3 are regulators of bone
metabolism.
MC3T3-E1 cells express osteoblast differentiation mar-
kers and form a mineralized extracellular matrix only after
exposure to L-ascorbic acid (AA), reduced vitamin C [10].
The role of AA in collagen matrix production in osteoblastic
cells, where procollagen synthesis, hydroxylation and secre-
tion are tightly coupled processes, has been well character-
ized. Collagen matrix formation is required to induce the
expression of osteoblastic phenotype, while AA increases
collagen matrix formation mainly by stimulating the hydrox-
ylation, secretion and processing of type I procollagened.
X. Wu et al. / Biochimica et Biophysica Acta 1641 (2003) 65–7066components [11]. Nakeda et al. [12] revealed that increased
extracellular Ca2 + levels (1.9–3.0 mM) significantly
increased type I collagen synthesis, monitored by the pro-
duction of procollagen type I carboxy-terminal peptide. An in
vitro study has shown that extracellular Ca2 + also induces
expression of bone morphogenetic protein (BMP)-2 and -4 in
human bone cells [12]. Inorganic phosphate or h-glycero-
phosphate as a PO4
3 precursor, with AA and/or a glucocor-
ticoid, has been applied to initiate mineralization in
osteoblastic MC3T3-E1 cells [13,14]. Increasing the concen-
tration of PO4
3 from 1 to 3 mM reduces the pre-mineraliza-
tion period from 2 weeks to 2 days [13]. A recent study has
indicated that PO4
3 at concentrations from 4 to 10mMalone,
even in the absence of AA, specifically induces osteopontin
(OPN) expression in MC3T3-E1 cells [15].
To exert biological activity, AA must transverse the
membrane from the extracellular space. The uptake of AA
is saturable and Na+-dependent in various types of cells and
tissues [16]. Two transporters for AA called sodium-depend-
ent vitamin C transporters (SVCT) 1 and 2 have been cloned
[17,18]. We demonstrated that only SVCT2 is expressed in
MC3T3-E1 cells, and that dexamethasone significantly
enhances the transport of AA and the expression of SVCT2
mRNA in MC3T3-E1 cells [18]. Although AA is essential in
expressing the phenotype in osteoblasts, how SVCT2
expression is regulated remains obscure. We therefore sought
to clarify the roles of Ca2 + and PO4
3 in the expression of
SVCT2 and of the differentiation marker, OPN, in MC3T3-
E1 osteoblastic cells.2. Materials and methods
2.1. Materials
MC3T3-E1 cells established from newborn mouse calva-
ria by Kodama et al. [19] were provided by Dr. T. MiyaharaFig. 1. Stimulatory effects of Ca2 + and PO4
3 on SVCT2 and OPN expression in M
density of 1106 with aMEM containing 5% FCS and incubated for 3 days. Con
conditions for the indicated periods. To examine the effect of increased concentrat
days, then for additional 72-h incubation in Ca2 +- or PO4
3-deficient medium and tr
RNA isolation and Northern blotting. Complementary DNA fragments for mSVCT
an internal control. This experiment was performed twice independently and the r(Toyama Medical and Pharmaceutical University, Toyama,
Japan). Alpha modifications of Eagle’s medium (aMEM)
containing 1.8 mM Ca2 + and 1.0 mM PO4
3 was purchased
from ICN Co. (Aurora, OH, USA). MEM vitamin, MEM
amino acids and MEM non-essential amino acid solutions
were purchased from GIBCO/BRL (Grand Island, NY,
USA). Fetal calf serum (FCS) free from Ca2 + or PO4
3
was prepared by dialysis against Ca2 +- or PO4
3-free Earle’s
solution. Calcium chloride, mono- and dibasic sodium phos-
phate, nifedipine and L-ascorbic acid were purchased from
Wako Pure Chemicals (Osaka, Japan). PO4
3 was prepared
from dibasic and monobasic sodium phosphate at a 4:1 molar
ratio as a 1 M solution (pH 7.0). Foscarnet (phosphonofor-
mic acid) was obtained from Sigma Chemical Co. (St. Louis,
MO, USA) and L-[1-14C]AA was from Perkin-Elmer Life
Science, Inc. (Boston, MA, USA) (0.295 MBq/Amol). Anti-
SVCT2 and anti-goat IgG conjugated with horseradish
peroxidase were purchased from Santa Cruz Biotechnology,
Inc. (Santa Cruz, CA, USA). TransIT-IL1 was purchased
from PanVera Co. (Madison, WI, USA). All other chemicals
were of reagent grade.
2.2. Cell cultures
MC3T3-E1 cells were maintained in aMEM containing
5% FCS. For Northern blot and Western blot analyses,
cells were plated at an initial density of 1106 cells per
10-cm dish. For uptake assay and reporter assay, cells
were plated at 5 104 cells per well of 24-well plates and
at 2 104 cells per well of 12-well plates, respectively.
After 3 days, when the cells reached confluence, media
were changed to give the desired experimental condition.
Ca2 +- or PO4
3-free aMEM media containing 5% dia-
lyzed FCS was the basal medium for cell manipulation.
Ca2 +- or PO4
3 -free aMEM was prepared in MEM
vitamin, MEM amino acids and MEM non-essential amino
acid solutions and in Ca2 +- or PO4
3-free Earle’s solution.C3T3-E1 cells. MC3T3-E1 cells were seeded in 10-cm culture dishes at the
fluent monolayers were incubated under Ca2 +- (A) or PO4
3- (B) deficient
ions of Ca2 + (C) or PO4
3 (D), cells were cultured in aMEM medium for 3
eated with increased Ca2 + or PO4
3 . Thereafter, cells were harvested for total
2 and mOPN were used as probes and blots were reprobed with 18s rRNA as
esults were qualitatively identical. One representative experiment is shown.
Fig. 2. Effects of calcium channel blocker, nifedipine, and phosphate
transporter inhibitor, foscarnet, on Ca2 +- and PO4
3-induced SVCT2 and
OPN expression. Unless otherwise indicated, experimental conditions were
identical to those indicated in Fig. 1. Cells were preincubated under Ca2 +- or
PO4
3-deficient medium with the indicated concentrations of nifedipine (A)
or foscarnet (B) for 6 h, then, cells were stimulated with Ca2 + (4 mM) or
PO4
3 (4 mM) in the presence or absence of inhibitors for an additional 66 h.
This experiment was performed twice independently and results were
qualitatively identical. One representative experiment is shown.
Fig. 3. Stimulatory effects of Ca2 + and PO4
3 on AA uptake (A) and SVCT2
protein levels (B) in MC3T3-E1 cells. Cells were seeded in 24-well culture
plates (A) or 10-cm dishes (B) with aMEM containing 5% FCS and
incubated for 24 h. Confluent monolayers were preincubated under Ca2 +-or
PO4
3-deficient conditions with 20 AM nifedipine or 0.6 mM foscarnet for 6
h. Then, cells were stimulated either with 4 mM Ca2 + or 4 mM PO4
3 in the
presence or absence of inhibitor for a further 66 h. Thereafter, 14C-AA-
uptake assay (A) or Western blotting for membrane protein (B) was
performed as described in Materials and methods. Data are expressed as
meansF S.D. of five to six independent cultures. This experiment was
performed twice independently, and results were qualitatively identical. One
representative experiment is shown. Significantly different from stimulant-
and inhibitor-free group (*P < 0.01; **P < 0.001). Significantly different
from stimulant alone group (yP < 0.01; zP< 0.001). Lane 1, 0 mM Ca2 + and
1.0 mM PO4
3; Lane 2, 4 mM Ca2 + and 1.0 mM PO4
3; Lane 3, 1.8 mM
Ca2 + and 0 mM PO4
3; Lane 4, 1.8 mM Ca2 + and 4.0 mM PO4
3.
X. Wu et al. / Biochimica et BiophyTo evaluate the effects of inhibitors, nifedipine and
foscarnet were added 6 h before calcium and phosphate
stimulation.
2.3. RNA isolation and Northern blotting
Total RNA from MC3T3-E1 cells was prepared using
TRIZOL regent by the acid ganidine phenol chloroform
method. Aliquot of total RNA (10 Ag) per lane was
resolved on 1% formaldehyde-agarose gels, transferred to
a Hybond-N+ membrane (Amersham Pharmacia, Piscat-
away, NJ, USA) and cross-linked by UV irradiation. Com-
plementary DNA fragments corresponding to mSVCT2 (nt
1099–1495; accession no. AB038145) and mOPN [20]
were labeled with [a-32P]-deoxycytidine 5V-triphosphate
(dCTP) and hybridized with RNA on the blots. Messenger
RNA signals were detected using a BAS 1500 Mac radio
imaging system (Fuji Film). All membranes were reprobed
with a 32P-labeled DNA for mouse 18s rRNA as an internal
control.
2.4. Western blotting
As SVCT2 protein exists in both intracellular pools and
plasma membranes [21,22], we detected the SVCT2
protein alteration at plasma membrane to illustrate the
effects of Ca2 + and PO4
3 . Following the treatment,
membrane fraction was prepared by the method of Aron-
son and Touster [23]. A 5-Ag protein sample was sepa-
rated by SDS-PAGE on a 10% gels and transferred to a
polyvinylidine difluoride membrane. Antigen on the mem-
brane was probed with goat anti-SVCT2 IgG and perox-
idase conjugated secondary antibody, then visualized by
enhanced chemiluminescence (ECL system, Amersham
Pharmacia).2.5. [14C]AA uptake
The uptake assay proceeded as described previously
[18,24], suggesting that within 1 h, the uptake of AA
appeared to increase linearly in this experimental condition.
Briefly, after rinsing with incubation media, cells were
incubated with 25 AM L-[14C]AA at 37 jC for 1 h, then
incorporated AA was measured using a liquid scintillation
sica Acta 1641 (2003) 65–70 67
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excess amount of cold AA at a concentration of 10 mM.
Specific uptake was calculated as cell-associated total radio-
activity minus nonspecific radioactivity. Results are pre-
sented as pmol AA/105 cells/h.
2.6. Construction of OPN promoter-luciferase reporter gene
and reporter assay
The plasmid used for transfection was a luciferase vector
bearing the mouse OPN gene promoter [25]. An OPN
promoter fragment (nt  253 from transcriptional start site
to nt + 28) was ligated to HindIII–BglIl site in pGV-B2
(Toyo Inki). The construct (pGV-B2-OPN) was verified by
sequencing the relevant portion. MC3T3-E1 cells were
transfected with pGV-B2-OPN using TransIT-IL1 transfec-
tion reagent according to the manufacturer’s protocol. Cells
were transfected with 1 Ag/well of pGV-B2-OPN or pGV-
B2. Ten hours after transfection, cells were treated with
stimulator for 66 h. When blocking activity of specific
inhibitors was tested, cells were pretreated with inhibitors
for 6 h, then treated with inhibitors and stimulators for
additional 66 h. After the treatment, cells were harvested
using passive lysis buffer (Promega) and the lysate were
used to evaluate luciferase activity and protein quantifica-
tion.
2.7. Statistical analysis
Numerical data are expressed as S.D. from six cultures.
Data were analyzed by ANOVA and the Tukey–Kramer
multiple comparisons test. Statistical significance was as-
sessed at the P < 0.05 level. Experiments were independ-
ently performed twice or three times and the results wereFig. 4. Effects of Ca2 +, PO4
3 (A) and their blockers (B) on OPN promoter-bearing
well plates and precultured for 24 h. Cells were then transfected with pGV-B2-OP
treated with inhibitors for 6 h, then treated with inhibitors (20 AMnifedipin; 0.6 mM
assay. Data are expressed as meansF S.D. of five to six independent cultures. This e
representative experiment is shown. Significantly different from stimulant- and in
group (yP < 0.001).qualitatively identical. Representative experiments are
shown.3. Results
To test the hypothesis that Ca2 + and PO4
3 are required
for SVCT2 and OPN expression, cells were cultured in either
Ca2 +- or PO4
3-deficient medium for the indicated periods.
Northern blotting indicated that deprivation of Ca2 + or
PO4
3  obviously and time-dependently reduced SVCT2
mRNA expression (Fig. 1A,B). Similarly, the absence of
Ca2 + or PO4
3 time-dependently decreased OPN expression
(Fig. 1A,B). Inductions of SVCT2 and OPN expression
appeared similar between the absence of Ca2 + and PO4
3.
Since the expression of SVCT2 and OPN in the absence
of Ca2 + or PO4
3 decreased, we inferred that the elevation of
Ca2 + or PO4
3 concentration would induce the expression of
SVCT2 and OPN. Fig. 1C and D shows that both Ca2 + and
PO4
3 at the concentrations of 1, 2 and 4 mM dose-depend-
ently increased SVCT2 and OPN expression after 72-h
treatment, consistent with the results indicated in the time
course experiments.
We examined whether calcium channels and a phosphate
transporter mediate Ca2 +- and PO4
3-induced SVCT2 and
OPN expression, respectively, utilizing the L type calcium
channel blocker, nifedipine and type III phosphate trans-
porter inhibitor, foscarnet (phosphonoformic acid). Fig. 2A
and B shows that nifedipine and foscarnet dose-dependently
and almost completely inhibited Ca2 +- and PO4
3-induced
SVCT2 and OPN expression, respectively.
Although Ca2 + and PO4
3 increased SVCT2 and OPN
expression, it was wondered whether Ca2 +- and PO4
3 -
induced SVCT2 expression was followed by an increase inluciferase reporter. Cells were plated at a density of 2 104 cells/well of 12-
N or pGV-B2 in Ca2 +- or PO4
3-free conditions. Ten hours later, cells were
foscarnet) and/or stimulators for additional 66 h, and harvested for luciferase
xperiment was performed twice, and results were qualitatively identical. One
hibitor-free group (*P< 0.001). Significantly different from stimulant alone
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SVCT2 protein levels. Fig. 3A shows that after 66-h exposure
to 4 mM Ca2 + or 4 mM PO4
3, the uptake of L-[14C]AA
significantly increased compared to those in the absence of
Ca2 + or PO4
3. Moreover, 20 AM nifedipine and 0.6 mM
foscarnet significantly inhibited the L-[14C]AA uptake in-
duced by 4 mM Ca2 + or PO4
3, respectively. Furthermore, as
shown in Fig. 3B, results fromWestern blotting demonstrated
that 4 mM Ca2 + or PO4
3 obviously increased the anti-
SVCT2 immunoreactive band, estimated to be 65 kDa, which
corresponded with the expected molecular weight of 66 kDa.
These results are consistent with those fromNorthern blotting
(Fig. 1) and uptake assay (Fig. 3A).
To clarify the possible mechanism on Ca2 +- and PO4
3-
induced OPN expression, we transiently transfected OPN
promoter bearing luciferase gene into the cells to observe the
effects of Ca2 +, PO4
3  and their blockers on the OPN
promoter activity. As shown in Fig. 4, Ca2 + and PO4
3
induced OPN promoter activity significantly. Nifedipine and
foscarnet significantly inhibited Ca2 +- and PO4
3-induced
increases of OPN promoter activity, corresponding to the
results from Northern blotting (Figs. 1 and 2).4. Discussion
Extracellular calcium controls many cellular functions
including secretion, cell growth, differentiation and motility
[26]; serum calcium appears to be one of the most essential
factors involved in bone formation and resorption [12]. On
the other hand, the ability of cells to actively transport
phosphate is a requirement for bone mineralization. The
present study is the first to demonstrate that Ca2 + and PO4
3
stimulated SVCT2, OPN expression and OPN promoter
activity in MC3T3-E1 cells, and that their effects were
almost completely abolished by the calcium channel blocker,
nifedipine, and the phosphate transporter inhibitor, foscarnet,
respectively.
At bone resorption sites, the osteoclasts consume large
amounts of energy to drive HCl secretion, which produces
high concentration of calcium, phosphate and water from the
strong basic calcium salt hydroxyapatite, [Ca3(PO4)2]3
Ca(OH)2, that comprises bone mineral [1]. Therefore, we
elevated Ca2 + and PO4
3 levels in the culture medium to
mimic the bone resorptive processes in vitro to clarify the
possible effects of the two ions on osteoblastic functions.
Our results indicated that either Ca2 + or PO4
3 deficiency
obviously reduced the SVCT2 and OPN expression, while
elevated Ca2 + or PO4
3 markedly induced the expression of
SVCT2 and OPN, which corresponds to some reports that
high concentrations of Ca2 + stimulate DNA synthesis,
notably increase mRNA levels of BMP-2, -4, and signifi-
cantly increase type I collagen synthesis [4,5,12]. On the
other hand, our results also demonstrated the pivotal role of
PO4
3 in SVCT2 and OPN expression, which are consistent
with the reports that PO4
3 regulates osteoblastic functions[13,15]. To the mechanism involving the Ca2 +- and PO4
3-
induced SVCT2 expression, we suggested that BMP-2 and -
4, IGF-I and -II might play critical roles in Ca2 +-induced
SVCT2 and OPN expression. In vitro study showed that high
concentration of extracellular Ca2 + notably increases autoc-
rinal production of BMP-2, -4 and IGF-I, -II, and these
growth factors are the effective stimulators of osteoblastic
differentiation and expression of differential markers
[4,5,12]. It is well known that PO4
3 enters into the cells to
promote bone mineralization and differentiation marker
expression; according to our results, we implicated that
PO4
3-induced SVCT2 and OPN expression might meet
the requirement of accelerated pre-mineralization [13]
because mineralization requires SVCT2-mediated AA
uptake and AA-dependent collagen matrix production in
MC3T3-E1 cells. Further study for clarifying the possible
mechanisms involving the effects of Ca2 + and PO4
3 on
SVCT2 and OPN expression was our future interest.
Results from L-[14C]AA uptake and Western blotting
indicated that Ca2 + and PO4
3 stimulated the expression of
functional SVCT2 protein in plasma membrane. Evaluating
L-[14C]AA uptake after 1-h exposure to Ca2 + or PO4
3,
neither Ca2 + nor PO4
3 stimulated AA uptake inferring that
increased L-[14C]AA uptake was a result of increased
SVCT2 steady state mRNA and protein expression. More-
over, utilizing combinations of these ions and the inhibitors,
we had been clear that effects of Ca2 + and PO4
3, each at the
concentration of 2 mM, on SVCT2 expression were not
synergistic, which means that they exert their effects in
separate pathways.
In addition, stimulation of SVCT2 and OPN expression
by elevated Ca2 + was unlikely through Ca2 +-sensitive
receptors or through release of the intracellular calcium
store [26]. This notion is supported by our findings that
nifedipine almost completely abolished Ca2 +-induced
SVCT2 and OPN expression, consistent with the in vitro
study indicating that elevated Ca2 + increases intracellular
Ca2 + influx in osteoblast cells [3]. However, PO4
3-stimu-
lated SVCT2 and OPN expressions were almost completely
inhibited by foscarnet, suggesting that the effect of PO4
3 on
SVCT2 and OPN expression depends upon PO4
3 entering
the cells via normal active transport, and that the actual
response is mediated by the increased intracellular phos-
phate levels.
As no SVCT2 promoter sequence was published, we do
not know whether Ca2 +- and PO4
3-induced SVCT2 expres-
sion resulted from an increase of its transcription activity;
whereas transient transfection assays indicated that positive
and negative transcription elements are localized in the OPN
promoter region [25], and PO4
3  did increase the OPN
promoter activity in MC3T3-E1 cells [15]. In this study,
we showed that Ca2 + and PO4
3 induced OPN promoter
activity, and that these effects were almost completely
abolished by nifedipine and foscarnet, respectively. There-
fore, we deduced that Ca2 +- and PO4
3-induced OPN tran-
scriptional activity might result from up-regulation of its
X. Wu et al. / Biochimica et Biophysica Acta 1641 (2003) 65–7070promoter activity. However, whether Ca2 + and PO4
3 
increase transcriptional factors binding to OPN promoter
region or not is worth further identifying. It is also likely that
Ca2 +- and PO4
3-induced OPN expression and promoter
activity might have resulted from increased AA uptake
owing to the up-regulation of SVCT2 expression induced
by Ca2 + or PO4
3, as AA did increase OPN expression in
vitro culture system through increasing ALP activity [15,27].
To further clarify the roles of SVCT2 on the OPN expression
is our future interest.
In summary, this study demonstrated that Ca2 + and PO4
3
entered cells through L-type calcium channel and phosphate
transporter to stimulate SVCT2 expression and increase
OPN mRNA levels through increasing OPN promoter activ-
ity, and that their effects were almost completely abolished
by their inhibitors.Acknowledgements
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